Adelaide, Südaustralien (ots/PRNewswire) – BioCina Pty Ltd, a global contract biopharmaceutical development and manufacturing organization (CDMO), announced that it has acquired exclusive rights to use CelluTx’s recombination-based plasmid system (RBPS) technology with BioCina’s CDMO customers. RBPS is a cutting-edge technology for the production of minicircle DNA (mcDNA), which involves site-specific recombination in a bacterial host to separate the minicircle containing the gene of interest from the rest of the plasmid backbone, including antibiotic resistance genes and replication origins. This new technology has several advantages over older mcDNA technologies, including scalability of the process, exceptionally high recombination efficiency, higher yields, simpler purification processes due to the clear separation of minicircles and miniplasmids, and the ability to produce larger minicircles that can accommodate complex gene cassettes . The slender structure of mcDNA leads to increased and prolonged transgene expression, making it less immunogenic and safer for the alive-Use. These advantages make RBPS a promising approach to advance the production of mcDNA and expand its applications in cell and gene therapies and other novel therapeutics. An example of such an application announced last year is this cGMP program that BioCina currently runs for GenomeFrontier with RBPS technology key to scale-up of GenomeFrontier’s CAR-T product.
BioCina Chief Executive Officer Mark W. Womack stated, “We are pleased to announce our partnership with CelluTx, allowing BioCina to offer this innovative technology exclusively to our customers around the world. We have already had great success deploying the technology across our customer portfolio and look forward to advancing many more customer programs with this technology.”
CelluTx CEO Maurits Geerlings said: “We are very pleased to collaborate with BioCina for the global deployment of RBPS Minicircle DNA technology. BioCina has proven capabilities and a high level of commitment to its customers, which was crucial to our partnership with BioCina.”
Womack added: “In addition, Australia offers one of the most attractive tax incentives in the world (up to 48.5% cash rebate), making it an ideal destination for biologics companies looking to invest in scaling up and manufacturing their products.”
Information about BioCina BioCina is a global contract biologics development and manufacturing company providing high quality and cost-effective cell line, process, analytical and formulation development, as well as clinical and commercial cGMP manufacturing of microbial, pDNA and mRNA modalities. BioCina’s first facility in Adelaide, South Australia is a testament to the quality of the company’s work. The company has a rich history of clinical and commercial drug development and manufacturing, supported by critical SMEs with an average tenure of more than 15 years. BioCina boasts excellent quality and has successfully passed regulatory inspections by the US FDA, Health Canada and EMA. It is approved by the Australian TGA for cGMP manufacturing of bulk drug products or active intermediates. By partnering with NovaCina, BioCina offers its customers a high quality filling and refining solution. BioCina is proud to have customers all over the world, including the USA, Europe and Asia Pacific. Since BioCina is not a drug developer, it only serves its customers’ products. BioCina is building a second large-scale, high-capacity facility for mammals and microorganisms in Australia, which should be ready for customers in 2026.
Australia offers one of the most attractive tax incentives in the world (up to 48.5% cash rebate), making it an ideal destination for biologics companies looking to invest in product expansion and manufacturing. For more information, see https://biocina.com.
Information about CelluTx CelluTx, LLC is a Wayne, PA-based biotech company that advances the cell and gene therapy community through the use of Dr. RBPS minicircle DNA technology invented by Peter Mayrhofer. RBPS technology is designed to ensure manufacturing scalability and optimal purity of clinical-grade Minicircle DNA. Because RBPS technology does not require bacterial backbone components, it offers a safer and more efficient DNA product for transfection, which is particularly important for CAR-TCR therapies. RBPS technology contributes to the optimization of various therapeutic applications in which DNA is a critical component, whether as a direct therapeutic agent, a therapeutic intermediate or as a source for other manufacturing processes. CelluTx has a strategic collaboration with Austria-based Supercoiled Genetics GmbH to support customers in the preclinical stage of research and development with RBPS technology.
Questions & Contact:
Media contact:
media@biocina.comLogo – https://mma.prnewswire.com/media/2346937/BioCina_New_Logo.jpg
Logo – https://mma.prnewswire.com/media/2427713/CelluTx_logo_3_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/biocina-erwirbt-the-exclusive-cdmo-rights-for-the-leading-minicircle-dna-technologieplattform-von-cellutx-302162323.html